https://www.einpresswire.com/article/451103050/clearside-biomedical-to-participate-in-2018-jmp-securities-life-sciences-conference
Clearside Biomedical to Participate in 2018 JMP Securities Life Sciences Conference
Jun 11, 2018 - Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with
to participatejmp securitieslife sciencesclearsidebiomedical
https://www.globenewswire.com/news-release/2025/05/14/3081594/0/en/Clearside-Biomedical-Announces-First-Quarter-2025-Financial-Results-and-Provides-Corporate-Update.html
Clearside Biomedical Announces First Quarter 2025 Financial
- Successful End-of-Phase 2 Meeting with FDA Led to Alignment on Phase 3 Program Design for CLS-AX in Wet AMD - - CLS-AX Targets Commercially Attractive...
first quarterclearsidebiomedicalannounces2025
https://www.fool.com/investing/2018/05/31/clearside-biomedical-stock-down-26-the-positive-da.aspx
Clearside Biomedical Stock Down 26%: The "Positive" Data That Wasn't | The Motley Fool
May 31, 2018 - Sometimes press release headlines and share prices don't match up.
https://stockhouse.com/companies/quote?symbol=clsdq
Clearside Biomedical Inc (EM) (EXPM:CLSDQ) Stock Price Today, News, Quote & History | Stockhouse
Get today's stock prices, news and investor discussion about Clearside Biomedical Inc (EM) (EXPM:CLSDQ). Research CLSDQ stock prices, stock quotes, stock...
https://www.fiercebiotech.com/biotech/clearside-slides-as-eye-drug-xipere-flunks-combination-study
Clearside slides as eye drug Xipere flunks combination study | Fierce Biotech
Nov 5, 2018 - Shares in Georgia small-cap Clearside Biomedical are in free fall this morning after the biotech revealed its top pipeline drug
clearsideslideseyedrug
https://www.benzinga.com/analyst-ratings/23/04/31887876/where-clearside-biomedical-stands-with-analysts
Where Clearside Biomedical Stands With Analysts - Benzinga
clearsidebiomedicalstandsanalystsbenzinga
https://www.fool.com/investing/2018/04/13/why-clearside-biomedical-inc-stock-gained-661-marc.aspx
Why Clearside Biomedical, Inc. Stock Gained 66.1% March | The Motley Fool
Apr 13, 2018 - Promising trial results helped trigger a short squeeze and sent the biotech's shares soaring.
https://www.biospace.com/clearside-biomedical-to-report-first-quarter-2024-financial-results-and-provide-corporate-update-on-thursday-may-9-2024
Clearside Biomedical to Report First Quarter 2024 Financial Results and Provide Corporate Update on...
Apr 30, 2024 - Clearside Biomedical, Inc., a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space,...
https://www.globenewswire.com/news-release/2025/05/21/3085610/0/en/Clearside-Biomedical-to-Participate-in-a-Fireside-Chat-at-the-Stifel-2025-Virtual-Ophthalmology-Forum.html
Clearside Biomedical to Participate in a Fireside Chat at
ALPHARETTA, Ga., May 21, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of...
a fireside chatto participateclearsidebiomedical
https://www.biospace.com/clearside-biomedical-announces-third-quarter-2020-financial-results-and-provides-corporate-update
Clearside Biomedical Announces Third Quarter 2020 Financial Results and Provides Corporate Update -...
Nov 11, 2020 - Initiation of Phase 1/2a Trialof CLS-AX (axitinib injectable suspension) for Wet Age-Related Macular DegenerationExpected by Year-End 2020
third quarter